Zobrazeno 1 - 10
of 729
pro vyhledávání: '"Wee Joo, Chng"'
Autor:
Sinan Xiong, Jianbiao Zhou, Tze King Tan, Tae-Hoon Chung, Tuan Zea Tan, Sabrina Hui-Min Toh, Nicole Xin Ning Tang, Yunlu Jia, Yi Xiang See, Melissa Jane Fullwood, Takaomi Sanda, Wee-Joo Chng
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-21 (2024)
Abstract Multiple myeloma is a hematological malignancy arising from immunoglobulin-secreting plasma cells. It remains poorly understood how chromatin rewiring of regulatory elements contributes to tumorigenesis and therapy resistance in myeloma. Her
Externí odkaz:
https://doaj.org/article/a72d588788c3426aa48efeac9ff0d625
Autor:
Naomi Aoki, Pin-Yen Chen, Wenming Chen, Wee Joo Chng, Gin Gin Gan, Yeow Tee Goh, Jian Hou, Jeffrey Huang, Kihyun Kim, Je Jung Lee, Jin Lu, Zoe K. McQuilten, Chang Ki Min, Elizabeth Moore, Laura Oliver, Neil A. Waters, Cameron Wellard, Erica M. Wood, Su-Peng Yeh, Andrew Spencer, the APAC MRDR Investigators
Publikováno v:
BMC Medical Research Methodology, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background Multiple myeloma (MM) is the second most common haematological cancer worldwide. Along with related diseases including monoclonal gammopathy of undetermined significance (MGUS), plasma cell leukaemia (PCL) and plasmacytoma, MM inc
Externí odkaz:
https://doaj.org/article/2d2da61cef2445e19dbba546c942f2a5
Autor:
Daniel A. Ang, Jean-Michel Carter, Kamalakshi Deka, Joel H. L. Tan, Jianbiao Zhou, Qingfeng Chen, Wee Joo Chng, Nathan Harmston, Yinghui Li
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-20 (2024)
Abstract In multiple myeloma, abnormal plasma cells establish oncogenic niches within the bone marrow by engaging the NF-κB pathway to nurture their survival while they accumulate pro-proliferative mutations. Under these conditions, many cases event
Externí odkaz:
https://doaj.org/article/76815108117b42dab68f4c265bee13e2
Autor:
Boheng Li, Qidi Zhou, Qin Wan, Xuan Qiao, Shangying Chen, Jianbiao Zhou, Zhijun Wuxiao, Lei Luo, Siok-Bian Ng, Jieping Li, Wee-Joo Chng
Publikováno v:
Clinical Epigenetics, Vol 15, Iss 1, Pp 1-16 (2023)
Abstract Background Overexpressed EZH2 is oncogenically involved in the pathogenesis of different cancerous contexts including extranodal natural killer/T cell lymphoma (ENKTL). However, the underlying mechanisms of EZH2 upregulation have not been fu
Externí odkaz:
https://doaj.org/article/8a31cc0ef54a4c1c9a923fd4f0e59efc
Autor:
Jianbiao Zhou, Wee-Joo Chng
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Acute myeloid leukemia (AML) is a complex and heterogeneous group of aggressive hematopoietic stem cell disease. The presence of diverse and functionally distinct populations of leukemia cells within the same patient’s bone marrow or blood poses a
Externí odkaz:
https://doaj.org/article/4195a1ce02d74646bf74c4d7f0641781
Autor:
Wendy W. L. Lee, Jing Quan Lim, Tiffany P. L. Tang, Daryl Tan, Ser Mei Koh, Kia Joo Puan, Liang Wei Wang, Jackwee Lim, Kim Peng Tan, Wee Joo Chng, Soon Thye Lim, Choon Kiat Ong, Olaf Rotzschke
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionNatural killer/T cell lymphoma (NKTL) is an aggressive malignancy associated with poor prognosis. This is largely due to limited treatment options, especially for relapsed patients. Immunotherapies like immune checkpoint inhibitors (ICI)
Externí odkaz:
https://doaj.org/article/16a07c7809ca40bdaf5cc823350af8f0
Autor:
Kamlesh Bisht, Taro Fukao, Marielle Chiron, Paul Richardson, Djordje Atanackovic, Eduardo Chini, Wee Joo Chng, Helgi Van De Velde, Fabio Malavasi
Publikováno v:
Cancer Medicine, Vol 12, Iss 20, Pp 20332-20352 (2023)
Abstract Background CD38 has been established as an important therapeutic target for multiple myeloma (MM), for which two CD38 antibodies are currently approved—daratumumab and isatuximab. CD38 is an ectoenzyme that degrades NAD and its precursors
Externí odkaz:
https://doaj.org/article/11c9e5f0da7846b4a4ba574aa7ba86ce
Autor:
Wee-Lee Chan, Vanessa Cui Lian Chong, Ian Jun Yan Wee, Li Mei Poon, Esther Hian Lee Chan, Joanne Lee, Yen-Lin Chee, Anand D. Jeyasekharan, Wee-Joo Chng, Miny Samuel, Sanjay de Mel
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract Rituximab-based chemo-immunotherapy is currently the standard first-line treatment for Waldenstrom macroglobulinaemia (WM), while ibrutinib has emerged as an alternative. In the absence of randomised trials (RCTs) comparing these regimens, t
Externí odkaz:
https://doaj.org/article/ff40f63f9b554a7eb8b5c591b218190b
Autor:
Slavisa Ninkovic, Simon J Harrison, Je-Jung Lee, Nick Murphy, Jae Hoon Lee, Jane Estell, Vivien M Chen, Noemi Horvath, Kihuyn Kim, Richard Eek, Bradley Augustson, Soo-Mee Bang, Shang-Yi Huang, Rajeev Rajagopal, Ferenc Szabo, Daniel Engeler, Belinda E Butcher, Peter Mollee, Brian Durie, Wee Joo Chng, Hang Quach
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
This multicentre, phase II study of the Australian Lymphoma and Leukaemia Group (ALLG) and the Asian Myeloma Network (AMN) investigated fixed-duration (18-month) treatment with carfilzomib (K), thalidomide (T), and dexamethasone (d; KTd) in patients
Externí odkaz:
https://doaj.org/article/59301dc2a06d4af9a911c8be6500565d
Autor:
Phyllis S.Y. Chong, Jing Yuan Chooi, Sze Lynn Julia Lim, Tae-Hoon Chung, Reinhard Brunmeir, Aaron Chung Yong Leow, Sabrina Hui Min Toh, Kalpnaa Balan, Muhamad Irfan Bin Azaman, Zhengwei Wu, Nagavidya Subramaniam, Leah A Vardy, Wee-Joo Chng
Publikováno v:
Haematologica, Vol 109, Iss 6 (2023)
REIIBP is a lysine methyltransferase aberrantly expressed through alternative promoter usage of NSD2 locus in t(4;14)-translocated multiple myeloma (MM). Clinically, t(4;14) translocation is an adverse prognostic factor found in approximately 15% of
Externí odkaz:
https://doaj.org/article/f19e38c9080845be90a8baff6bb37aa2